2208
Y. Hayakawa et al. / Tetrahedron 61 (2005) 2203–2209
which was stirred for an additional 5 min. To this mixture, a
1.0 M toluene solution of TBHP (0.24 mL, 0.24 mmol) was
added, and stirring was continued for 10 min. The insoluble
material was filtered off. Concentration of the filtrate
afforded a crude product, which was purified by column
chromatography (eluent, 20:1 CH2Cl2/CH3OH) to afford 25
(986 mg, 97% yield): 31P NMR (162 MHz) d K3.33;
HRMS (ESIC) calcd for C50H62N5O14PSiNa (MCNaC)
1038.37, found 1038.37. The 1H NMR spectrum (400 MHz)
was identical to those of an authentic sample.11b Dideoxy-
ribonucleoside phosphates 22,20 23,20 and 2420 were
COSMOSIL 5C18-AR-II [4.6 (diameter) mm!25 (height)
cm]; flow rate, 1.0 mL/min; detection, 254 nm; eluent and
gradient, [AZa 1.0 mM ammonium acetate buffer solution
in H2O, BZa 0.2 mM ammonium acetate buffer solution
in a 20:80 mixture of H2O and acetonitrile, 0–90 min with
a linear gradient from A 100% to A 70%/B 30%];
temperature, 40 8C. In both cases of 18 and 19, only a
peak due to the starting material was detected, indicating
that 18 and 19 underwent no decomposition under the above
reaction condition.
1
prepared in a similar manner. H NMR, 31P NMR, and
4.6. Solid-phase synthesis of
0
0
HRMS (ESIC) spectral data of these compounds were as
follows.
5 GpApCpTpCpTpCpTpTpApGpCpTpApApT3 (27)
Chain elongation of the oligodeoxyribonucleotide was
carried out on a 0.2 mmol scale according to the reaction
cycle shown in Table 3. The resulting fully protected
oligonucleotide was exposed to concentrated ammonia
at 25 8C for 2 h and then 55 8C for 12 h to afford the
target compound: HRMS (ESIK) of 27 calcd for
C156H196N54O96P15 (MK3HC) 1608.96, found 1608.93.
1
4.4.1. Compound 22. H NMR (400 MHz) d 0.10 (s, 6H),
0.90 (s, 9H), 1.91 (s, 3H), 2.18–2.29 (m, 2H), 2.65–2.85 (m,
3H), 3.10–3.15 (m, 1H), 3.41–3.50 (m, 2H), 3.78, 3.79 (2 s,
6H), 4.01–4.46 (m, 7H), 5.30–5.34 (m, 1H), 6.14, 6.22 (2 t,
1H, JZ6.8 Hz), 6.49–6.53 (m, 1H), 6.78–6.83 (m, 4H),
7.22–7.31 (m, 9H), 7.37–7.39 (m, 2H), 7.52–7.55 (m, 2H),
7.59–7.63 (m, 1H), 8.04, 8.06 (2 br, 2H), 8.14, 8.15 (2 s,
1H), 8.72, 8.75 (2 s, 1H), 9.16, 9.18 (2 s, 1H); 31P NMR
(162 MHz) d K3.15, K3.22; HRMS (ESIC) calcd for
C57H66N8O13PSi (MCHC) 1129.43, found 1129.34.
4.7. NMR analysis of the reaction of 17 and 20 using 5 as
a promoter
The phosphoramidite 17 (32.2 mg, 43 mmol) was weighed
into a dry NMR tube equipped with a Young’s tap and
dissolved in CD3CN (0.3 mL). To this sample, a solution of
the carboxylic acid 5 (9.3 mg, 44 mmol) in CD3CN (0.3 mL)
was added with a syringe under an argon stream. The NMR
4.4.2. Compound 23. 1H NMR (400 MHz) d 0.08, 0.09 (2 s,
6H), 0.89, 0.89 (2 s, 9H), 1.87, 1.90 (2 s, 3H), 2.14–2.41 (m,
3H), 2.67 (q, 1H, JZ6 Hz), 2.76 (t, 1H, JZ6 Hz), 2.94–2.99
(m, 1H), 3.43–3.53 (m, 2H), 3.79–3.80 (4 s, 6H), 3.98–4.03
(m, 1H), 4.11–4.31 (m, 4H), 4.37–4.42 (m, 2H), 5.13–5.18
(m, 1H), 6.19, 6.23 (2 t, 1H, JZ6.4 Hz), 6.27–6.30 (m, 1H),
6.85–6.88 (m, 4H), 7.22–7.42 (m, 11H), 7.48–7.52 (m, 2H),
7.57–7.62 (m, 1H), 7.92–7.94 (m, 2H), 8.11–8.13(m, 1H),
9.23 (br, 1H), 9.25 (br, 1H); 31P NMR (162 MHz) d K3.11,
K3.26; HRMS (ESIC) calcd for C56H66N6O14PSi (MC
HC) 1105.41, found 1105.44.
1
tube was sealed by the Young’s tap, and the H and 31P
NMR spectra were recorded. After the measurements were
carried out, a CD3CN (0.3 mL) solution of the nucleoside 20
(13.0 mg, 37 mmol) was introduced into the tube in a similar
manner for subsequent NMR analysis. The experiment was
conducted in a similar manner with trichloroacetic acid or
salicylic acid.
1
4.4.3. Compound 24. H NMR (400 MHz) d 0.10 (s, 6H),
0.90 (s, 9H), 1.16–1.29 (m, 6H), 1.99, 2.05 (2 s, 3H), 2.27–
2.42 (m, 2H), 2.64–2.82 (m, 5H), 3.30–3.42 (m, 2H), 3.73
(q, 1H, JZ7.2 Hz), 3.79, 3.79 (2 s, 6H), 3.91–4.00 (m, 1H),
4.18–4.39 (m, 5H), 4.56–4.63 (m, 1H), 5.23–5.31 (m, 1H),
5.83–6.11 (m, 1H), 6.14–6.30 (m, 1H), 6.81–6.84 (m, 4H),
7.21–7.39 (m, 9H), 7.73, 7.73 (2 s, 1H), 9.02, 9.84 (2 s, 1H),
10.06, 10.54 (2 s, 1H), 12.21, 12.33 (2 s, 1H); 31P NMR
(162 MHz) K2.34, K3.04; HRMS (ESIC) calcd for
C54H68N8O14PSi (M C HC) 1111.44, found 1111.51.
Acknowledgements
This work was supported in part by Grants-in-Aid for
Scientific Research (Nos. 16011223 and 16350086) from
the Ministry of Education, Science, Sports and Culture of
Japan, and Mitsui Chemicals, Inc.
References and notes
4.5. Stability of purine nucleosides 18 and 19 to
trichloroacetic acid in acetonitrile
1. Beaucage, S. L.; Iyer, R. P. Tetrahedron 1993, 49, 6123–6194
and references cited therein.
A mixture of the nucleoside 18 (45.2 mg, 0.10 mmol) or 19
(46.9 mg, 0.10 mmol) and MS 3A (60 mg) in dry aceto-
nitrile (0.8 mL) was stirred for 30 min. An acetonitrile
(0.2 mL) solution of trichloroacetic acid (18 mg,
0.11 mmol) was then added to the mixture, which was
stirred for an additional 30 min. To this mixture were added
a NaHCO3-saturated aqueous solution (ca. 2 mL) and
dichloromethane (ca. 3 mL), and stirring was continued
for 10 min. The lower organic layer was separated, dried
over sodium sulfate, concentrated, and then subjected to
HPLC analysis under the following conditions: column,
2. For the mechanism of the condensation reaction of a nucleo-
side phosphoramidite and a nucleoside using 1H-tetrazole as
HX, see: (a) Dahl, B. H.; Nielsen, J.; Dahl, O. Nucleic Acids
Res. 1987, 15, 1729–1743. (b) Barone, A. D.; Tang, J.-Y.;
Caruthers, M. H. Nucleic Acids Res. 1984, 12, 4051–4061.
(c) Berner, S.; Mu¨hlegger, K.; Seliger, H. Nucleic Acids Res.
1989, 17, 853–864. For related works, see: (d) Nurminen, E. J.;
¨
Mattinen, J. K.; Lonnberg, H. J. Chem. Soc., Perkin Trans. 2
1998, 1621–1628. (e) Nurminen, E. J.; Mattinen, J. K.;
¨
Lonnberg, H. J. Chem. Soc., Perkin Trans. 2 1999, 2551–2556.